Incorporating the sample correlation into the testing of two endpoints in clinical trials

被引:1
|
作者
Sarkar, Sanat [1 ]
Rom, Dror [2 ]
McTague, Jaclyn [2 ]
机构
[1] Temple Univ, Dept Stat Sci, Philadelphia, PA 19122 USA
[2] Logecal Data Analyt, 996 Old Eagle Sch Rd,Suite 1106, Wayne, PA 19087 USA
关键词
Bonferroni test; closed testing; familywise-error rate; multiple endpoints; Simes’ test;
D O I
10.1080/10543406.2021.1895191
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We introduce an improved Bonferroni method for testing two primary endpoints in clinical trial settings using a new data-adaptive critical value that explicitly incorporates the sample correlation coefficient. Our methodology is developed for the usual Student's t-test statistics for testing the means under normal distributional setting with unknown population correlation and variances. Specifically, we construct a confidence interval for the unknown population correlation and show that the estimated type-1 error rate of the Bonferroni method with the population correlation being estimated by its lower confidence limit can be bounded from above less conservatively than using the traditional Bonferroni upper bound. We also compare the new procedure with other procedures commonly used for the multiple testing problem addressed in this paper.
引用
收藏
页码:391 / 402
页数:12
相关论文
共 50 条
  • [31] Surrogate Endpoints in Clinical Trials
    Elliott, Michael R.
    ANNUAL REVIEW OF STATISTICS AND ITS APPLICATION, 2023, 10 : 75 - 96
  • [32] Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes
    Homma, Gosuke
    Yoshida, Takuma
    PHARMACEUTICAL STATISTICS, 2024, 23 (01) : 46 - 59
  • [33] Correlation between bacteriologic and clinical endpoints in trials of acute otitis media - Reply
    Dagan, R
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (10) : 937 - 937
  • [34] Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials
    Chu, Guotao
    Zhu, Xiaochen
    Wu, Jiaju
    Tang, Yike
    Luu, Jonathan
    He, Chunsheng
    Huang, Shu-Pang
    Liu, Liangang
    Hsieh, Hsin-Ju
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [35] Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials
    Hung, H. M. James
    Wang, Sue-Jane
    O'Neill, Robert
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) : 1201 - 1210
  • [36] Estimating significance level and power comparisons for testing multiple endpoints in clinical trials
    Gong, JJ
    Pinheiro, JC
    DeMets, DL
    CONTROLLED CLINICAL TRIALS, 2000, 21 (04): : 313 - 329
  • [37] Blinded sample size recalculation in clinical trials incorporating historical data
    Hees, Katharina
    Kieser, Meinhard
    CONTEMPORARY CLINICAL TRIALS, 2017, 63 : 2 - 7
  • [38] Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints
    Song, James X.
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2009, 53 (04) : 1201 - 1207
  • [39] Bayesian sample size for exploratory clinical trials incorporating historical data
    Whitehead, John
    Valdes-Marquez, Elsa
    Johnson, Patrick
    Graham, Gordon
    STATISTICS IN MEDICINE, 2008, 27 (13) : 2307 - 2327
  • [40] Sample size determination in clinical trials with multiple co-primary binary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    STATISTICS IN MEDICINE, 2010, 29 (21) : 2169 - 2179